11:50 – 12.00 Marko Jakopović: Introduction
Diagnostics and staging
Moderator: Bojan Zarić
12:00 – 12:20 Fran Seiwerth: Appropriate options for lung cancer diagnosis
12:20 – 12:35 Kristina Krpina: Initial results of National lung cancer screening program
12:35 – 12:50 Miroslav Samaržija: Predictive models in lung cancer screening
12:50 – 13:10 Maja Hrabak Paar: New TNM 9th edition staging proposal
13:10 – 13:30 Fran Borovečki: Comprehensive genomic profiling in thoracic oncology in Croatia
13:30 – 13:50 Bojan Zarić: The role of ctDNA in non-small cell lung cancer
13:50 – 14:20 Satellite symposium Roche
14:20 – 14:40 Coffee break
Early stage lung cancer
Moderator: Davorin Radosavljević
14:40 – 15:00 Lovorka Batelja -Vuletić: Importance of MPR and pCR in the era of neodjuvant immunotherapy
15:00 – 15:20 Maximillian Hochmair: Peri-operative treatment of lung cancer
Radiotherapy
Moderator: Tihana Boraska Jelavić
15:20 – 15:40 Tihana Pavić: Modern radiotherapy in thoracic oncology
15:40 – 16:00 Marko Jakopović: Stage III lung cancer – concomitant or sequential CRT in the era of immunotherapy
16:00-16:30 Satellite symposium MSD
16:30 – 16:50 Coffee break
Special considerations
Moderator: Davorin Radosavljević
16:50 – 17:10 Sonja Badovinac: Endobronchial interventions in lung cancers – indications and outcomes
17:10 – 17: 30 Luka Simetić: Thoracic sarcomas
17:30 – 17: 50 Tomi Kovačević: The role of cannabinoids in palliative care of lung cancer patients
17:50 – 18:10 Sandra Karabatić: What is the role of lung cancer nurse in lung cancer pathway through the disease?
20:00 Get together
Small-cell lung cancer
Moderator: Urška Janžić
08:30 – 08:50 Dražena Srdić: Systemic treatment of SCLC – current standards and future options
08:50 – 09:10 Tihana Boraska Jelavić: Radiation therapy in extensive stage SCLC – thoracic and brain radiotherapy in the era of immunotherapy
09:10 – 09:30 Dorian Hiršl: The role of surgery in small – cell lung cancer
Targeted treatments
Moderator: Katja Mohorčić
09:30 – 09:50 Lela Bitar: Treatment of EGFR positive lung cancer patients
09:50 – 10:10 Sanja Pleština: How to choose upfront ALK inhibitor?
10:10 – 10:30 Urška Janžić: New targets in NSCLC – treatment options
10:30 – 10:50 Jasna Radić: Antibody – drug conjugates in lung cancer – therapeutic implications
10:50 – 11:20 Satellite symposium AstraZeneca
11:20 – 11:40 Coffee break
Immunotherapy
Moderator: Davorin Radosavljević
11:40 – 11:50 Marko Jakopović: Is immunotherapy a game changer? Introduction to the session
11:50 – 12:10 Katja Mohorčić: Mono vs combo immunotherapy in patients with expression of PD-L1 ≥ 50%
12:10 – 12:30 Suzana Mladinov: Optimal duration of immunotherapy in NSCLC
12:30 – 12:50 Marijo Boban: Re-challenge of immunotherapy – when and why?
12:50 – 13:10 Ivana Canjko: Side – effects of immunotherapy – special considerations in the era of combination therapies
Special considerations
Moderator: Tihana Boraska Jelavić
13:10 – 13:30 Feđa Džubur: Indications for ICU admission in lung cancer patients or when not to turn down admission of lung cancer patient in ICU?
13:30 – 13:50 Vide Popović: Pleural mesothelioma
13:50 – 14:10 Marko Jakopović: Is chemotherapy dead?
14:10 – 14:30 Latinka Basara: Approach to lung cancer patient – psychologist point of view
14:30 – 14:50 Davorin Radosavljević: What will future of treatment of lung cancer look like?
14:50 Closing remarks